Shineway Pharmaceutical reports 16.3% drop in nine-month turnover

China Shineway Pharmaceutical Group Limited reported a 16.3% decrease in its total turnover for the nine months ended 30 September 2025, reaching RMB 2,415 million. This decline is in comparison to the same period in 2024, according to management accounts not yet reviewed by auditors.

All product categories experienced a decrease in turnover. Injection products saw the steepest decline of 23.6% to RMB786 million, followed by soft capsule products, which fell by 13.7% to RMB337 million. Granule products decreased by 14.5% to RMB391 million, while TCM formula granule products dropped 11.8% to RMB726 million. Products in other forms decreased by 6.1% to RMB175 million.

The product mix for the nine months ended September 30, 2025, showed injection products accounting for 32.5% of total turnover, soft capsule products 14.0%, granule products 16.2%, and TCM formula granule products 30.1%. Shareholders and investors are advised to exercise caution when dealing in the company's shares.